Source comparison
Long COVID Researchers Thymosin Alpha-1 Protocol: Dosing Comparison
Stanford Post-Acute COVID Clinic 1.6mg SC twice weekly 12 weeks minimum, extend to 20 weeks if biomarkers abnormal CD4+/CD8+ ratio normalization + PROMIS Fatigue score Most conservative timeline. Appropriate for newly diagnosed long COVID with mild-moderate sy
This comparison does not assign a generated winner or score.
- Stanford Post-Acute COVID Clinic
- 1.6mg SC twice weekly
- 12 weeks minimum, extend to 20 weeks if biomarkers abnormal
- CD4+/CD8+ ratio normalization + PROMIS Fatigue score
- Most conservative timeline. Appropriate for newly diagnosed long COVID with mild-moderate symptoms
- Yale Long COVID Multidisciplinary Care Center
- 1.6mg SC twice weekly for 8 weeks, then once weekly for 8 weeks
- 16 weeks total (taper phase included)
- IL-6 reduction + 6-minute walk test improvement
- Includes mandatory taper. Reduces risk of symptom rebound after abrupt discontinuation
- Mount Sinai Center for Post-COVID Care
- 8–16 weeks (biomarker-guided)
- T-cell exhaustion marker reduction (PD-1, TIM-3 expression)
- Research-intensive protocol requiring flow cytometry. Not accessible outside academic centers
- European long COVID peptide protocols (aggregated literature)
- 1.6–3.2mg SC twice weekly
- 12–24 weeks
- Patient-reported outcome improvement (fatigue, cognitive function)
- Higher dose range than U.S. protocols. No evidence that >1.6mg improves outcomes